Your Source for Venture Capital and Private Equity Financings

HotSpot Therapeutics Closes $100M Series C

2021-11-29
BOSTON, MA, HotSpot Therapeutics, a biotechnology company, has closed a $100 million Series C financing led by Pivotal bioVenture Partners.
HotSpot Therapeutics, a biotechnology company pioneering the discovery and development of first-in-class allosteric therapies targeting regulatory sites on proteins referred to as 'natural hotspots,' announced the close of its oversubscribed $100 million Series C financing, bringing its total funding to $190 million.

Led by Pivotal bioVenture Partners, with significant participation by LSP and B Capital Group, the round includes new investors Monashee Investment Management, LLC, CaaS Capital Management, Revelation Partners and Pavilion Capital, as well as participation from previous investors, Atlas Venture, Sofinnova Partners, SR One Capital Management, funds managed by Tekla Capital Management, LLC, and MRL Ventures Fund.
(c) by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000+ startups and 5,000+ VC investors